Physician profile
Sumit Mahajan
NPI 1659350916
$4,297.23
in general payments reported to CMS, 2019-2025
33 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $41.48 · 2021: $847 · 2022: $738 · 2023: $775 · 2024: $797 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.99 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $792.93 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $375.68 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $362.59 | 2019-2024 | Xarelto |
| Mylan Specialty L.P. | $270.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.12 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.03 | 2023-2024 | Caplyta |
| Boston Scientific Corporation | $173.79 | 2022 | |
| Edwards Lifesciences Corporation | $150.02 | 2021 | |
| Daiichi Sankyo INC. | $146.02 | 2021 | |
| Amgen INC. | $143.98 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $130.17 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $126.95 | 2022-2024 | Ingrezza |
| Intuitive Surgical, INC. | $118.53 | 2024 | |
| Novo Nordisk INC | $112.86 | 2019-2023 | Wegovy |
| Sanofi Pasteur INC. | $112.76 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $112.19 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $111.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.93 | 2021-2022 | |
| Pfizer INC. | $71.69 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $61.60 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.65 | 2019-2025 | Xifaxan |
| Erbe USA INC | $50.00 | 2024 | |
| Dexcom, INC. | $43.95 | 2021-2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $43.82 | 2021-2022 | |
| Almatica Pharma LLC | $40.63 | 2021-2022 | |
| Abbott Laboratories | $35.59 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.57 | 2022 | |
| Circassia INC. | $30.31 | 2019 | |
| Lilly USA, LLC | $27.18 | 2024 | Mounjaro |
| Exact Sciences Corporation | $24.11 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $24.02 | 2025 | |
| Viatris Specialty LLC | $22.50 | 2025 | Yupelri |
| Shionogi INC | $21.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Mahajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.